This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
hVIVO plc (AIM & Euronext: HVO) , (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using
hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Avacta, Cyanconnode, DeepVerge,
hVIVO (HVO), (formerly Open Orphan plc), a specialist contract research organisation, announced that it has signed a £6.8m contract with a leading pharmaceutical company based in Asia Pacific, to test
hVIVO plc (AIM & Euronext: HVO) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Blencowe, Conroy, DG,
hVIVO saw record revenues for another year in 2022 as demand for its human challenge trials accelerated. And 2023 could see further gains.
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Baron, Cadence, Cleantech,
hVIVO (HVO) (formerly Open Orphan plc), a specialist contract research organisation, announced a trading update for the period ended 31 December 2022.
EBITDA significantly ahead of expectations Orderbook growth and improved operational delivery lays strong foundations for future growth